Clinical Trial Update: Primary Resistance Mechanisms of ALK TKIs

View source ↗

Summary

This clinical trial entry outlines a study to investigate primary resistance mechanisms to ALK inhibitors in patients with ALK-positive advanced non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alectinib (alectinib)
• Brigatinib (brigatinib)
• Ceritinib (ceritinib)
• Crizotinib (crizotinib)
• lorlatinib (lorlatinib)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: ALK-positive Advanced NSCLC Patients, Primary Resistance | Status: NOT_YET_RECRUITING